Virtual Library
Start Your Search
Y. Zheng
Author of
-
+
P2.03b - Poster Session with Presenters Present (ID 465)
- Event: WCLC 2016
- Type: Poster Presenters Present
- Track: Advanced NSCLC
- Presentations: 1
- Moderators:
- Coordinates: 12/06/2016, 14:30 - 15:45, Hall B (Poster Area)
-
+
P2.03b-078 - MET Gene Amplification and Overexpression in Chinese NSCLC Patients without EGFR Mutations (ID 4501)
14:30 - 14:30 | Author(s): Y. Zheng
- Abstract
Background:
The prevalence and clinic pathologic characteristics of MET amplification and overexpression in Chinese patients with non-small cell lung cancer (NSCLC) remain unknown. In this multicenter study, we focus on revealing the frequency and clinic pathological characteristics of MET amplification and explore the predictive value of MET amplification and overexpression status to survival in Chinese NSCLC patients.
Methods:
MET amplification was detected by fluorescence in-situ hybridization (FISH) in 791 patients with EGFR wild-type samples. MET protein expression was detected by immunohistochemistry.
Results:
In total, 8 patients were identified as harboring MET amplification from 791 NSCLC patients with EGFR wild-type. Among these 8 patients, one was with histology of adeno-squamous carcinoma and 7 of adenocarcinoma. There was no statistically significant difference among age, gender, smoking status and histologic type between patients with and without MET amplification. MET amplification was more frequent in advanced stage and solid predominant subtype of adenocarcinoma. MET protein expression was performed in 395 patients and 138 were positive. Patients with MET protein expression positive had an inferior overall survival compared to those without MET protein expression (45.0 months vs 65.8 months; P=0.001) . Multivariate analysis revealed that MET expression was independent prognostic factor for poor overall survival（HR=1.497,P=0.017),while,the MET amplification shows weak relevance for overall survival (HR=1.974,P=0.251).
Conclusion:
MET amplification was rare in Chinese NSCLC without EGFR mutation, with a prevalence of about 1%. MET expression but not amplification could be an independent prognostic factor for shorter OS among those EGFR wild-type NSCLC patients .
-
+
P3.02a - Poster Session with Presenters Present (ID 470)
- Event: WCLC 2016
- Type: Poster Presenters Present
- Track: Advanced NSCLC
- Presentations: 1
- Moderators:
- Coordinates: 12/07/2016, 14:30 - 15:45, Hall B (Poster Area)
-
+
P3.02a-003 - ALK and ROS1 Rearrangements, Coexistence and Treatment in EGFR-Wild Type Lung Adenocarcinoma - A Multicentre Study of 732 Cases (ID 4499)
14:30 - 14:30 | Author(s): Y. Zheng
- Abstract
Background:
Anaplastic lymphoma kinase (ALK) and c-ros oncogene 1 (ROS1) rearrangements represent two of the most frequency fusion targets in lung adenocarcinoma. The aim of this study was to investigate the clinicopathological characteristics, coexistence and treatment of ALK and ROS1- rearrangement patients in lung adenocarcinoma without EGFR mutations.
Methods:
Patients who harbored EGFR wild-type gene were screened for ALK and ROS1 gene in four Hospitals in China. ALK and ROS1 rearrangements were detected using RT-PCR. Progression free survival curves were plotted using the Kaplane-Meier method.
Results:
Seven hundred and thirty-two patients enrolled in current study.Of the 732 patients, the median age was 59 years (range: 28–81). ALK and ROS1 rearrangements were detected in 89 (12.2%) and 32 (4.4%) patients,respectively. One patient was identified with ALK/ROS1 coexistence. Both of ALK and ROS1 positive were predominantly found in younger and non-smokers. More patients with ALK/ROS1 rearrangements were associated with TTF1 expression，napsin A expression and solid predominant adenocarcinoma subtype(Figure 1 ). Figure 1Figure 2
Conclusion:
ALK and ROS1 rearrangements frequency was enriched in EGFR wild-type patients and ALK/ROS1 coexistence was rare. The ALK and ROS1 arrangements were associated with age, smoking status, TTF1 expression, napsin A expression and solid predominant adnocarcinoma subtype.
